0
Abstract: Slide Presentations |

SAFETY AND EFFICACY OF LINEZOLID AND AZITHROMYCIN IN THE TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS FREE TO VIEW

Sudhir K. Agarwal, MD, FCCP*; Deependra Kumar, MBBS
Author and Funding Information

Institute of Medical Sciences, BHU, Varanasi, India



Chest. 2006;130(4_MeetingAbstracts):95S. doi:10.1378/chest.130.5.1454
Text Size: A A A
Published online

Abstract

PURPOSE: To determine the safety and efficacy of linezolid (L), azithromycin (AZ), along with kanamycin, pyrazinamide, ethionamide and ethambutol in Indian patients having multi-drug resistant tuberculosis.

METHODS: Forty-six patients (study group), aged 18 years to 50 years having multi-drug resistant tuberculosis (MDR-TB) were given linezolid, azithromycin along with kanamycin, pyrazinamide, ethionamide and ethambutol under direct supervision. Forty-four patients (control group) were given kanamycin, pyrazinamide, ethionamide and ethambutol. All patients were HIV negative, smear-positive, non-pregnant and had been receiving anti-tuberculosis drugs for an average of 74 weeks (31 to 128 weeks). All patients had isolates resistant to both isoniazid and rifampicin. Linezolid was given for 6 months. Kanamycin was given in the dose of 25 mg/kg body weight on alternate days for 16 weeks. Pyrazinamide was stopped after 12 weeks of therapy. The course of treatment was 18 months. Sputum examination for acid-fast bacilli was done every 4 weeks.

RESULTS: Forty-two cases in the study group and 41 in the control group completed the treatment. The sputum negative conversion in the study group (82%) was significantly higher than in the control group (58%). The radiological improvement rate was 48% in the study group,which was significantly higher than that in the control group (29%) (P<0.01). The closure rate of the lung cavities in the study group (66%) was higher than in the control group (48%) (P<0.05). No significant difference was found in the side-effects between the two groups.

CONCLUSION: The regimen including linezolid, azithromycin, kanamycin and other second-line anti-TB drugs was effective and safe for the patients with MDR-TB.

CLINICAL IMPLICATIONS: Chemotherapy with linezolid, azithromycin, kanamycin, pyrazinamide, ethionamide and ethambutol seems to be promising for Indian patients having MDR-TB.

DISCLOSURE: Sudhir Agarwal, None.

Monday, October 23, 2006

10:30 AM - 12:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543